A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy
PHASE2CompletedINTERVENTIONAL
Enrollment
2
Participants
Timeline
Start Date
May 15, 2014
Primary Completion Date
January 31, 2016
Study Completion Date
July 15, 2016
Conditions
c-MET Positive Gastric Cancer
Interventions
DRUG
crizotinib
crizotinib 250mg bid daily
Trial Locations (1)
135-710
Samsung Medical center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT02435108 - A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy | Biotech Hunter | Biotech Hunter